Search research articles
Contact Us
Filters
Showing results (461-470 of 504) with videos related to
Page
of 51
Sort By:
Blood
|
February 17, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Cancer Research
|
March 4, 2017
Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice
Bernard Leroy, Mandy L Ballinger, Fanny Baran-Marszak, et al.
American Journal of Hematology
|
November 9, 2022
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study
Shai Levi, Yotam Bronstein, Neta Goldschmidt, et al.
Leukemia
|
September 11, 2024
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
Daniel Hägerstrand, Blaž Oder, Diego Cortese, et al.
Haematologica
|
September 29, 2018
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
Panagiotis Baliakas, Theodoros Moysiadis, Anastasia Hadzidimitriou, et al.
Blood
|
September 6, 2013
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, et al.
The Journal of Experimental Medicine
|
August 15, 2012
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
Davide Rossi, Vladimir Trifonov, Marco Fangazio, et al.
British Journal of Haematology
|
August 15, 2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling
Riccardo Moia, Lodovico Terzi di Bergamo, Donatella Talotta, et al.
Hemasphere
|
July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
Riccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
European Journal of Haematology
|
July 25, 2018
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
Massimo Gentile, Tait D Shanafelt, Francesca Romana Mauro, et al.
Page
of 51
Search research articles
Search
Showing results (461-470 of 504) with videos related to
Sort By:
Page
of 51
Blood
|
February 17, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Cancer Research
|
March 4, 2017
Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice
Bernard Leroy, Mandy L Ballinger, Fanny Baran-Marszak, et al.
American Journal of Hematology
|
November 9, 2022
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study
Shai Levi, Yotam Bronstein, Neta Goldschmidt, et al.
Leukemia
|
September 11, 2024
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
Daniel Hägerstrand, Blaž Oder, Diego Cortese, et al.
Haematologica
|
September 29, 2018
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
Panagiotis Baliakas, Theodoros Moysiadis, Anastasia Hadzidimitriou, et al.
Blood
|
September 6, 2013
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, et al.
The Journal of Experimental Medicine
|
August 15, 2012
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
Davide Rossi, Vladimir Trifonov, Marco Fangazio, et al.
British Journal of Haematology
|
August 15, 2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling
Riccardo Moia, Lodovico Terzi di Bergamo, Donatella Talotta, et al.
Hemasphere
|
July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
Riccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
European Journal of Haematology
|
July 25, 2018
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
Massimo Gentile, Tait D Shanafelt, Francesca Romana Mauro, et al.
Page
of 51